Determination of 5-fluorouracil and its prodrug tegafur in plasma and tissue by high-performance liquid chromatography in a single injection: Validation for application in clinical pharmacokinetic studies

Therapeutic Drug Monitoring

Volumn 25, Issue 2, 2003, Pages 221-228

  Zufía, Laura ^a   Aldaz, Azucena ^a   Castellanos, Carmen ^a   Giráldez, Joaquín ^a  

^a Universidad Pública de Navarra   (Spain)

Author keywords

5 Fu; HPLC; Pharmacokinetic; Tegafur; Validation

Indexed keywords

5 BROMOURACIL; ANTINEOPLASTIC AGENT; ETOFYLLINE; FLUOROURACIL; PRODRUG; TEGAFUR;

ADENOCARCINOMA; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG MONITORING; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INJECTION; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RAT; STANDARD; VALIDATION PROCESS;

ANTIMETABOLITES, ANTINEOPLASTIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLUOROURACIL; HUMANS; PRODRUGS; TEGAFUR; TISSUE DISTRIBUTION;

EID: 0037382224     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200304000-00013     Document Type: Article

References (41)

1. Lokich J, Bothe A, Fine N, et al. Phase I study of protracted venous infusion of 5-fluorouracil. Cancer. 1981;48:2565-8.
2. Lokich J, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a MidAtlantic Oncology Program Study. J Clin Oncol. 1989;7:425-32.
3. Hansen RM, Quebbeman E, Anderson T. 5-Fluorouracil by protracted venous infusion. A review of current progress. Oncology. 1989;46:245-50.
4. Vogelzang N. Continuous infusion chemotherapy: a critical review. J Clin Oncol. 1984;2:1289-304.
5. Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998;16:301-98.
6. 1-(2′-Tetrahydrofuryl)-5fluorouracil. Clin Cancer Res. 1998;4:1085-8.
7. Au JL, Sadee W. The pharmacology of ftorafur (R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil). Recent Results Cancer Res. 1981;76:100-14.
8. Au JL, Wu AT, Friedman MA, et al. Pharmacokinetics and metabolism of ftorafur in man. Cancer Treat Rep. 1979;63:343-50.
9. Lamont EB, Schilsky RL. The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res. 1999;5:2289-96.
10. Andersen E, Pedersen H. Oral ftorafur versus intravenous 5-fluorouracil. Acta Oncol. 1987;26:433-6.
11. Ansfield FJ, Kallas GJ, Singson JP. Phase I-II studies of oral tegafur (ftorafur). J Clin Oncol. 1983;1:107-10.
12. Bjerkeset T, Fjosne HE. Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon, or rectum. Oncology (Basel). 1986;43:212-5.
13. Kajanti MJ, Pyrhonen S, Maiche A. Oral tegafur in the treatment of metastatic breast cancer: phase II study. Eur J Cancer. 1993; 29A:863-6.
14. Palmeri S, Gebbia V, Russo A, et al. Oral tegafur in the treatment of gastrointestinal tract cancers: a Phase II study. Br J Cancer. 1990;61:475-8.
15. Kobayashi K, Jodrell DI, Ratain MJ. Pharmacodynamicpharmacokinetic relationships and therapeutic drug monitoring. Cancer Surv. 1993;17:512-79.
16. Marunaka T, Umeno Y. Determination of fluorouracil and pyrimidine bases in plasma by gas chromatography-chemical-ionization mass fragmentography. J Chromatogr. 1980;222:382-6.
17. Marunaka T, Umeno Y, Yoshida K, et al. The high-pressure liquidchromatographic determination of ftorafur and g.l.c.-massspectrometric determination of fluorouracil and uracil in biologic materials after oral administration of uracil plus ftorafur. J Pharm Sci. 1980;69:1296-300.
18. Kubo M, Sasabe H, Shimizu T. Highly sensitive method for the determination of 5-fluorouracil in biologic samples in the presence of 2′-deoxy-5-fluorouridine [floxuridine] by gas chromatographymass spectrometry. J Chromatogr. 1991;564:137-45.
19. Aubert C, Luccioni C, Coassolo P, et al. Comparative determinations of fluorouracil in plasma using g.c.-m.s. and h.p.l.c. ArzneimForsch. 1981;31:2048-53.
20. Isomura H, Higuchi S, Kawamura S. Gas chromatographic-mass spectrometric determination of plasma fluorouracil after administration of 5-fluoro-1-(hexylcarbamoyl) uracil to dogs and humans. J Chromatogr. 1981;224:423-9.
21. Odagiri H, Ichihara S, Semura E, et al. Determination of 5-fluorouracil in plasma and liver after oral administration of 5′-deoxy-5-fluorouridine using gas chromatography-mass spectrometry. J Pharmacobiodyn. 1988;11:234-40.
22. Kok RM, De Jong APJM, Van Groeningen CJ, et al. Highly sensitive determination of 5-fluorouracil in human plasma by capillary gas chromatography and negative-ion chemical-ionization mass spectrometry. J Chromatogr. 1985;343:59-66.
23. Anderson LW, Parker RJ, Collins JM, et al. Gas-chromatographicmass-spectrometric method for routine monitoring of 5-fluorouracil in plasma of patients receiving low-level protracted infusions. J Chromatogr. 1992;581:195-201.
24. Bates CD, Watson DG, Willmott N, et al. Analysis of 5-fluorouracil in human plasma by gas chromatography-negative-ion chemical-ionization mass spectrometry (GC-NICIMS) with stableisotope dilution. J Pharm Biomed Anal. 1991;9:19-21.
25. Matsushima E, Yoshida K, Kitamura R, et al. Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyrimidine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. J Chromatogr. 1997;691:94-104.
26. Ackland SP, Garg MB, Dunstan RH. Simultaneous determination of dihydrofluorouracil and 5-fluorouracil in plasma by highperformance liquid chromatography. Anal Biochem. 1997;246:79-85.
27. Compagnon P, Thiberville L, Moore N, et al. Simple highperformance liquid-chromatographic method for the quantitation of 5-fluorouracil in human plasma. J Chromatogr B. 1996;677:380-3.
28. Gamelin E, Boisdron-Celle M, Turcant A, et al. Rapid and sensitive high-performance liquid-chromatographic analysis of halogenopyrimidines in plasma. J Chromatogr B. 1997;695:409-16.
29. Wung WE, Howell SB. Simultaneous liquid chromatography of fluorouracil, uridine, hypoxanthine, xanthine, uric acid, allopurinol, and oxypurinol in plasma. Clin Chem. 1980;26:1704-8.
30. Buckpitt AR, Boyd MR. Sensitive method for determination of fluorouracil and 5-fluoro-2′-deoxyuridine [floxuridine] in human plasma by high-pressure liquid chromatography. Anal Biochem. 1980;106:432-7.
31. LaCreta FP, Williams WM. High-performance liquid-chromatographic analysis of fluoropyrimidine nucleosides and fluorouracil in plasma. J Chromatogr. 1987;414:197-201.
32. Wattanatorn W, McLeod HL, Cassidy J, et al. High-performance liquid-chromatographic assay of 5-fluorouracil in human erythrocytes, plasma and whole blood. J Chromatogr B. 1997;692:233-7.
33. Del Nozal MJ, Bernal JL, Pampliega A, et al. Determination of the concentrations of fluorouracil and its metabolites in rabbit plasma and tissues by high-performance liquid chromatography. J Chromatogr B. 1994;656:397-405.
34. Moore MJ, Bunting P, Yuan S, et al. Development and validation of a limited sampling strategy for 5-fluorouracil given by bolus intravenous administration. Ther Drug Monit. 1993;15:394-9.
35. Christophidis N, Mihaly G, Vajda F, et al. Comparison of liquid and gas-liquid chromatographic assays of 5-fluorouracil in plasma. Clin Chem. 1979;25:83-6.
36. Schaaf LJ, Ferry DG, Hung CT, et al. Analysis of 5′-deoxy-5fluorouridine and 5-fluorouracil in human plasma and urine by high-performance liquid chromatography. J Chromatogr. 1985; 342:303-13.
37. Escoriaza J, Aldaz A, Calvo E, et al. Simple and sensitive determination of 5-fluorouracil in plasma by high-performance liquid chromatography. Application to clinical pharmacokinetic studies. J Chromatogr B. 1999;736:97-102.
38. x rectal cancer after chemoradiation: 5-fluorouracil vs Tegafur. Int J Radiat Oncol Biol Phys. 2001;51:1264-70.
39. Jarugula VR, Boudinot FD. High-performance liquid chromatographic determination of 5-fluorouracil and its prodrugs, tegafur and 4-deoxy-5-fluorouracil, in rat plasma. J Chromatogr B. 1996; 677:199-203.
40. Schaaf LJ, Dobbs B, Edwards IR, et al. Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients. Eur J Clin Pharmacol. 1987;32:411-8.
41. Schaaf LJ, Dobbs BR, Edwards IR, et al. The in vitro stability of doxifluridine in whole blood and plasma. Eur J Clin Pharmacol. 1988;34:533-4.